Results 161 to 170 of about 24,911 (203)
Decitabine-Driven Foetal Haemoglobin Induction in Townes Mice and Human Erythroblasts. [PDF]
EJHaemCarol Illa A +6 more
europepmc +1 more source
Correction to "Treating Hematological Malignancies With OR-2100, an Orally Bioavailable Prodrug of Decitabine". [PDF]
Cancer Scieuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2009
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Daskalakis, Michael +2 more
+6 more sources
The pyrimidine analogs, 5-azacytidine (azacitidine, Vidaza) and its deoxy derivative, 5-aza-2'-deoxycytidine (decitabine, Dacogen, are the most widely used inhibitors of DNA methylation which trigger demethylation leading to a consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Daskalakis, Michael +2 more
+6 more sources
Reactions Weekly, 2014
Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2'-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Hackanson, Björn, Daskalakis, Michael
openaire +4 more sources
Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2'-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Hackanson, Björn, Daskalakis, Michael
openaire +4 more sources
Drugs, 2006
Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells. In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with ...
Kate, McKeage, Katherine F, Croom
openaire +2 more sources
Decitabine is a hypomethylating agent. Its action in DNA leads to the reactivation of tumour suppressor genes and the subsequent differentiation of cancer cells. In a randomised, phase III trial in patients (n = 170) with myelodysplastic syndromes (MDS), intravenous decitabine (45 mg/m(2)/day for 3 consecutive days every 6 weeks) combined with ...
Kate, McKeage, Katherine F, Croom
openaire +2 more sources
Current Opinion in Oncology, 2003
Decitabine is a cytosine analogue synthesized in the 1960s that is currently enjoying a revival of interest prompted by the elucidation of DNA methylation inhibition as its major mechanism of action, along with increased understanding of the role of DNA methylation in epigenetic dysregulation in cancer.
openaire +2 more sources
Decitabine is a cytosine analogue synthesized in the 1960s that is currently enjoying a revival of interest prompted by the elucidation of DNA methylation inhibition as its major mechanism of action, along with increased understanding of the role of DNA methylation in epigenetic dysregulation in cancer.
openaire +2 more sources